Your browser doesn't support javascript.
loading
Differentiation-inducing factor-1 prevents hepatic stellate cell activation through inhibiting GSK3ß inactivation.
Furukawa, Shohei; Yamaguchi, Momoka; Ooka, Akira; Kikuchi, Haruhisa; Ishikawa, Tomohisa; Saito, Shin-Ya.
Affiliation
  • Furukawa S; Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga Ward, Shizuoka City, Shizuoka, 422-8526, Japan; Kyoto Pharmaceutical Industries, Ltd., 38 Nishinokyo, Tsukinowa-cho, Nakagyo-ku, Kyoto, 604-8444, Japan.
  • Yamaguchi M; Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga Ward, Shizuoka City, Shizuoka, 422-8526, Japan. Electronic address: yamamomo@u-shizuoka-ken.ac.jp.
  • Ooka A; Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga Ward, Shizuoka City, Shizuoka, 422-8526, Japan.
  • Kikuchi H; Laboratory of Natural Product Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 980-8578, Japan.
  • Ishikawa T; Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga Ward, Shizuoka City, Shizuoka, 422-8526, Japan.
  • Saito SY; Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga Ward, Shizuoka City, Shizuoka, 422-8526, Japan.
Biochem Biophys Res Commun ; 520(1): 140-144, 2019 11 26.
Article in En | MEDLINE | ID: mdl-31582219
ABSTRACT
Differentiation-inducing factor-1 (DIF-1), a morphogen produced by the cellular slime mold Dictyostelium discoideum, is a natural product that has attracted considerable attention for its antitumor properties. Here, we report a novel inhibitory effect of DIF-1 on the activation of hepatic stellate cells (HSCs) responsible for liver fibrosis. DIF-1 drastically inhibited transdifferentiation of quiescent HSCs into myofibroblastic activated HSCs in a concentration-dependent manner, thus conferring an antifibrotic effect against in the liver. Neither SQ22536, an adenylate cyclase inhibitor, nor ODQ, a guanylate cyclase inhibitor, showed any effect on the inhibition of HSC activation by DIF-1. In contrast, TWS119, a glycogen synthase kinase 3ß (GSK3ß) inhibitor, attenuated the inhibitory effect of DIF-1. Moreover, the level of inactive GSK3ß (phosphorylated at Ser9) was significantly reduced by DIF-1. DIF-1 also inhibited nuclear translocation of ß-catenin and reduced the level of non-phospho (active) ß-catenin. These results suggest that DIF-1 inhibits HSC activation by disrupting the Wnt/ß-catenin signaling pathway through dephosphorylation of GSK3ß. We propose that DIF-1 is a possible candidate as a therapeutic agent for preventing liver fibrosis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatic Stellate Cells / Glycogen Synthase Kinase 3 beta / Hexanones Limits: Animals Language: En Journal: Biochem Biophys Res Commun Year: 2019 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatic Stellate Cells / Glycogen Synthase Kinase 3 beta / Hexanones Limits: Animals Language: En Journal: Biochem Biophys Res Commun Year: 2019 Document type: Article Affiliation country:
...